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Abstract
Informing clinical practice in a learning health system requires good
causal inference methods in order to estimate the effects of drugs from
observational studies. However, these methods rely on untestable as-
sumptions, making it difficult to evaluate whether the returned drug
effect estimates from a method are reliable, or to compare the effec-
tiveness of different methods. In this work, we provide a reference set
of the effects of drugs on various side effects based on public clini-
cal trials data. We improve on prior reference sets by constructing a
consistent statistical definition of positive and negative controls and
by constructing our controls from clinical trials instead of drug pack-
age inserts or the literature. We also provide an example application,
where we use the reference set to evaluate a suite of causal inference
methods on observational medical claims data. In doing so, we find
that the treatment effects estimated using inverse propensity weighting
with propensity scores estimated via machine learning accurately sep-
arate the positive controls from the negative controls in our reference
set.
Background & Summary
The increased availability of electronic data collected from routine health-
care operation provides an opportunity to use observational studies to guide
clinical practice as well as conduct research on developing novel methods for
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causal inference [5,14,17]. In parallel, the FDA and other stakeholders have
expressed interest in using “real world data,” an umbrella term that includes
observational studies, to make regulatory decisions for drugs [9, 12, 19, 24]
due to limitations of clinical trials [1,22]. Making regulatory or clinical prac-
tice decisions using observational studies requires justification—that apply-
ing causal inference methods on electronic health data reaches correct con-
clusions about the effectiveness and side effects of clinical interventions.
The practice of evidence-based medicine emphasizes the use of clinical
trials as the backbone of medical research [31]. In such a trial, patients
are randomly assigning candidate interventions so that the patients treated
with each intervention are not systematically different from one another. In
contrast, patients treated with different interventions in observational data
collected from clinical practice are likely to be systematically different, hin-
dering the comparison of outcomes between the two groups. Causal inference
methods can adjust for the differences between populations, but can only
provide accuracy guarantees under untestable assumptions [26]. As a result,
evidence generated from observational data remains limited in its use, even
in situations where clinical trial derived evidence is not available [7,10,21,33].
Research quantifying the accuracy of observational studies in making cor-
rect causal inferences would clarify the extent to which these studies should
influence clinical practice. One approach for such quantification is to ex-
amine for the presence of a set of known drug effects using observational
data and check their concordance with the known drug effects [11, 27]. To
the extent that these drug-effect associations reflect causal questions asked
of observational data, the resulting concordance between the estimated ef-
fects quantifies the accuracy of the observational studies for answering causal
questions. These known drug-effect associations also allow a comparison of
different inference methods to determine when and why some techniques
work better than others; and, in turn, guides the search for better causal
inference methods for healthcare data.
In this work, we create and provide a drug-effect reference set based on
known drug effects curated from ClinicalTrials.gov data. With appropriate
filtering and processing, the drug-effect pairs generated from clinical trial
data provide a good source of known hypotheses to test using observational
data. We identify clinical trials that directly compare medications and use
the side effects reported during those trials to create positive controls where
one drug causes a side effect relative to another and negative controls where
both drugs have roughly equal side effect rates. By using clinical trials
and applying a method to control the false discovery rate of admitting a
drug-effect pair in our reference set, this reference set primarily contains
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drug-effect hypotheses with a known causal relationship.
Previous drug-effect reference sets, such as those created by OMOP [27]
and EU-ADR [11], were created from FDA labels and publications. How-
ever, the ability of observational studies to detect the effects listed in these
reference sets is relatively low [20,28,29], possibly due to complexities in how
FDA labels are created, biases in the publication process, limitations of the
study methods, or the statistical definition of negative controls. Our new
reference set, based on filtered clinical trial data, comes with a precise sta-
tistical definition of negative and positive controls with statistical guarantees
about the error rates in each of those sets as well as strong empirical backing
in that it corresponds well with observed effects in observational data.
Methods
ClinicalTrials.gov serves as a public repository for clinical trials carried out
in the United States and abroad. The database contains pre-registration in-
formation, trial status, and results as provided by researchers conducting the
trials. Many clinical trials are legally required to report results to Clinical-
Trials.gov, and thus there is reasonably high coverage for both trial details
and results [15], with the June 4, 2020 version of the database containing
33,701 clinical trials. We extracted controls from that set of trials. Figure 1
provides an overview of the analysis pipeline with counts of potential trials
and controls at each major step.
Extracting trials with an active comparator design
The results section of each clinical trial record consists of a set of study
arms as well as the primary outcomes and side effects associated with each
arm. The study arms, primary outcomes and side effects are all specified in
natural language and must be mapped to standardized terminologies. For
this reference set, we discarded the primary outcome data as it is difficult
to consistently map outcomes to observational data due to a wide diversity
of measurements and a lack of standardized terminology. We instead chose
to focus on the side effect information because it is generally specified using
MedDRA terminology and is also available in observational datasets. We
obtained a standardized version of these side effects (i.e. outcomes) by map-
ping them to ICD10 using the dictionary mappings contained within UMLS
2019AB [6]. We only performed direct mappings from MedDRA to ICD10
to maintain high mapping precision.
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Treatment arms in the raw ClinicalTrials.gov data are specified in an ad-
hoc manner in terms of brand names, ingredients, dosages and/or more spe-
cialized names. As a preliminary step, we filtered out all treatment arms with
fewer than 100 patients as trials of that size are frequently noisy. We then
used the RxNorm [23] API to transform the text descriptions into RxNorm
ingredient sets with a minimum match score of 51. Placebos and treatment
arms with more than one ingredient (due to either containing multiple drugs
or drugs with multiple active ingredients) were filtered out. As an additional
quality control step, we also filtered out study arms that contain plus signs
in their names that usually indicate combination treatments that RxNorm
is not always able to detect.
One important feature of ClinicalTrials.gov data is that it often contains
overlapping trials where the same drug combinations have been tested by
multiple researchers. We combined similar drug records, which accounted for
26.7% of our original records. Event and participant counts are aggregated
across similar trials whenever trials with identical drug combinations and
outcome measurements are encountered. Similarly, we also aggregated across
arms where the same drugs were evaluated with different dosages. Doing so
had the dual purpose of strengthening the ability to detect weaker effects
while also helping discard cases where different trials had conflicting results.
At the end of this process, we were left with 19,822 unique drug vs. drug
treatment comparisons.
Creating positive and negative controls
Each drug-drug comparison was then further processed in order to create
positive and negative controls. Positive controls consist of a pair of drugs
where one is believed to cause a higher incidence of outcomes relative to
another drug. Negative controls consist of a pair of drugs that are believed
to not have a measurable effect on that outcome relative to each other. Note
that all effects are defined as relative effects; a positive control could be due
to one drug in the pair having a protective effect or the other drug having a
harmful effect. Correspondingly, negative controls might contain drugs that
are either roughly equally harmful or beneficial.
It is not possible to statistically prove that the relative effect difference
between two drugs is exactly zero. Instead, we follow standard practice by
testing whether or not the relative effect is within an equivalence margin [34];
we used a margin of 1.25 on the odds ratio scale. Therefore, the negative
controls in our set have evidence from clinical trials suggesting an odds ratio
between 0.8 and 1.25. Symmetrically, the positive controls in our set have
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evidence from a clinical trial suggesting an odds ratio either less than 0.8
or greater than 1.25. This setup ensures that there is a precise statistical
definition for both positive and negative controls such that every possible
drug-effect pair must be either a positive or a negative and not both.
One issue with clinical trial side effect information is that many trials
do not contain enough data to make any conclusion about particular side
effects in either a positive or negative way. In order to adjust for this, we
explicitly dropped all controls where the number of events in both arms
is too small to be statistically significant as either a negative or positive
control at the α = 0.05 level, resulting in 292 possible negative controls
and 5,107 possible positive controls. We then separately compute p-values
for whether a control is positive or negative. The p-value for determining
whether a control is positive was calculated by taking the minimum p-value
of two Fisher exact tests for whether the odds ratio is greater than 0.8 or less
than 1.25 and adjusting by a factor of two to control for multiple testing.
The p-value for determining whether a control is negative was calculated
by taking the maximum p-value of two Fisher exact tests for whether the
odds ratio is less than 0.8 or greater than 1.25 [16]. Finally, we used the
computed p-values to select positive and negative controls by applying the
Benjamini–Hochberg procedure [4] to limit the false discovery rate (FDR) at
α = 0.05. The resulting set consists of 217 significant positive controls and
76 significant negative controls.
Data Records
The resulting positive and negative controls are publicly available as a CSV
file uploaded to https://osf.io/h7gu8. Each reference set entry consists
of a single row with the following columns:
STUDIES: The ClinicalTrials.gov trial identifiers that provided the raw
data for this reference set entry.
DIRECTION: An indication of whether this entry is a positive or nega-
tive control and the direction of the estimated effect if it is a positive
control. Negative controls are marked by an “=” sign and positive con-
trols are marked by a “<” or “>” sign indicating whether drug1 has an
estimated hazard rate lower or higher than drug2.
ICD10_CODES: The ICD10 codes that correspond to the outcome for
that reference set entry.
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ATC_CODES1/ATC_CODE2: The ATC codes corresponding to the drugs
for that reference set entry.
Technical Validation
Validating the accuracy and utility of this reference set consists of two parts:
1) establishing the accuracy of the transformation of the textual content from
ClinicalTrials.gov records into reference set controls, and 2) verifying that
the resulting controls can be detected as observed effects in observational
datasets.
We verified the accuracy of the transformation of the textual content
manually. We manually checked all of the drug-effects pairs in our final set
and verified that the corresponding ClinicalTrials.gov records matched the
controls in our reference set. An entry was considered correct when the
event counts, drug names, outcome names, ATC code mapping, and ICD10
code mapping are all consistent with the source clinical trials. All our final
controls passed these correctness checks and appeared to correctly reflect the
clinical trial standard.
A second means of estimating correctness is to evaluate whether the
effects specified in this reference set can be detected in observational datasets.
If the reference set is not valid, it should not be possible to recover any of
the specified effects with more accuracy than random chance. As part of our
Usage Notes, we evaluated this reference set on a commonly used US claims
dataset and achieved significantly better than random chance precision and
recall for recovering the known effects in our reference set (Figure 2).
Usage Notes
The primary use case for this new reference set is to help compare causal
inference methods for conducting observational studies that guide clinical
practice [18, 30]. As an illustrative example, we have carried out an eval-
uation comparing unadjusted, propensity score matched [26], and inverse
propensity weighting [2, 25] estimation of the hazard ratio between treat-
ments using this new reference set. This comparison serves a dual purpose
of providing baselines for future methods work and of illustrating how to
quantify the performance of causal inference methods using the clinical tri-
als derived reference set.
We performed all of our analysis on version 7.1 of the Optum Clinformat-
ics Data Mart. The Optum dataset is a large US commercial claims dataset
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containing over 88 million patients and is frequently used for observational
studies [33]. Our overall study design for each entry in the reference and each
compared method is to create new-user cohorts where patients are starting
on one of the two drugs being compared. All cohorts were constructed sys-
tematically using the first drug reimbursement claim for either of the two
drugs as the index time. At most 100,000 patients were sampled for each
drug with a minimum patient count of 100. Outcomes were measured until
records were censored. Of the 293 controls in our reference set, the Optum
Clinformatics R© Data Mart 7.1 had enough patients to evaluate 191 of them
(115 positive controls and 76 negative controls).
As a simple baseline, we performed an unadjusted analysis by fitting a
Cox model for the outcome codes with a single parameter for the treatment.
The resulting coefficient on that parameter serves as our effect estimate for
the treatment.
We also performed a propensity score matched analysis in order to bet-
ter control for confounding. We estimated propensity scores using a logistic
regression model trained on low dimension representations extracted from
a patient records’ prescriptions, diagnoses, and procedures [32]. This rep-
resentation enabled us to train highly effective propensity models at much
lower computational cost. We then performed 1-1 greedy matching on the
logit scale with a caliper of 0.1 to obtain propensity score matched cohorts.
Finally, we estimated the relative effect of one drug over another by fitting a
Cox model with a single parameter for the treatment. As in the unadjusted
analysis, the coefficient for that parameter was used as our effect estimate
for the treatment.
We performed a third analysis with inverse propensity weighting (IPW),
also referred to as inverse probability of treatment weighting in the literature.
We used the IPW estimator in a marginal structural model with Cox propor-
tional hazards for the treatment only [2,25]. We added additional weighting
for the optimally weighted average treatment effect under homoskedastic-
ity [13] to improve the variance, finite sample performance and stability of
the IPW estimator by targeting the treatment effect in regions of overlap.
The propensity score was fit using logistic regression on the low dimension
representation, as described above.
We evaluated each method’s ability to reproduce the known effects in the
reference set in terms of both being able to detect the correct effect direc-
tion for the positive controls and in terms of being able to correctly identify
that the positive control had stronger effects than the negative controls. We
evaluate performance in terms of two metrics, precision and recall. Precision
is the fraction of returned results that are correctly assigned as positive with
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the correct direction. Recall is the fraction of recovered positive controls.
We evaluate all of our metrics on weighted control sets with weights applied
so that the weighted ratio between positives and negatives is 1-1. For our
particular clinical trial reference set, we used a weight of 1/76 on our nega-
tive controls and 1/115 on our positive controls. We evaluate precision and
recall at different effect size thresholds where we label all results with esti-
mated effect sizes below that threshold as negative and all results with effect
sizes above that threshold as positive. This matches the core definition of
positive and negative controls in terms of stronger versus weaker effects. We
do not know the optimal threshold a priori so we sweep all possible effect
size thresholds to obtain a precision-recall plot that shows the performance
of each method over a range of possible thresholds. One note is unlike stan-
dard precision-recall curves for evaluating prediction models, the recall never
reaches 100% because it is impossible to recover an incorrectly estimated di-
rection of a positive control just by changing the effect size threshold.
Figure 2 contains the resulting precision-recall plot for the three evaluated
methods on the complete control set. In addition to the tested methods,
we also show the random chance baseline which represents how randomly
guessing effects would obtain 25% precision and at most 50% recall. Note
that because of the way precision is defined, both the effect size and direction
need to be correct, which at random occurs 25% of the time. Similarly, recall
is the fraction of correctly identified positive controls and guessing at random
can get either the effect size or the direction wrong, thus capping the recall
at 50%. This precision-recall data can also be used to obtain performance
estimates for various methods at particular thresholds as shown in table 1
for the propensity score matching method.
Propensity score matching performs well, and this plot lends more ev-
idence for the utility of propensity score matching as an adjustment pro-
cedure, which matches well with prior literature [3, 8, 26]. However, IPW
improves the precision and recall, warranting more widespread use of the
method in healthcare data. The improved performance of IPW in our anal-
ysis may come from using the optimally weighted average treatment effect
with homoskedastic errors, which has been shown to improve performance
over naïve IPW when the overlap between the propensity scores of treated
and control units is low [13].
As a comparison, we also performed the same experiment using the
OMOP and EU-ADR reference sets. Figure 3 shows the corresponding per-
formance using the positive and negative controls from those reference sets.
The OMOP reference set consists of 165 positive controls and 234 nega-
tive controls. We had enough patients to run 125 positive controls and 163
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negative controls from the OMOP reference set. Similarly, the EU-ADR ref-
erence set consists of 43 positive controls and 50 negative controls, and we
had enough patients to run 29 positive controls and 39 negative controls.
Similar to prior work [29], precision of all three methods is low when es-
timated using the OMOP and EU-ADR reference sets, which corresponds
with either more difficult to detect effects or lower quality of ground truth
in each entry.
Code availability
The code used to generate this dataset can be found at https://github.
com/Lalaland/clinical-public under an MIT license. The software re-
quires the user to obtain a copy of UMLS and an XML dump from Clinic-
Trials.gov. For our reference set, we used the 2019AB release of UMLS and
the June 4, 2020 XML release from ClinicalTrials.gov.
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Randomized experimental 
trial records with results
(n = 33,701) 
Treatment comparisons 
with at least 200 patients
(n = 4,399,155)
Valid drug vs drug 
treatment comparisons 
(n = 27,117)
Unique drug vs drug 
treatment comparisions 
(n = 19,822)
Positive controls that have an odds 
ratio either >1.25 or <0.8 and are 
statistically significant at α = 0.05
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correction via the 
Benjamini-Hochberg procedure 
(n = 217)
Possible positive controls 
with enough events to allow for 
statistical significance at α = 0.05
according to the Fisher exact test
(n = 5,107)
Possible negative controls 
with enough events to allow for 
statistical significance at α = 0.05
according to the Fisher exact test
(n = 292)
Negative controls that have an odds 
ratio either >1.25 or <0.8 and are 
statistically significant at α = 0.05
according to the Fisher exact test 
with multiple hypothesis testing 
correction via the 
Benjamini-Hochberg procedure 
(n = 76)
Figure 1: An overview of our reference set construction process.
Hazard Ratio Threshold Precision Recall
2 85.7 % 10.4%
1.5 82.8% 20.9%
1.25 82.9% 44.3%
Table 1: Precision and recall of the propensity score matching method at
several hazard ratio thresholds according to our clinical trials reference set
computed on Optum claims data.
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Figure 2: Precision and recall of effect estimates computed on Optum claims
data for 191 controls in our clinical trial reference set. An estimate for a
positive control is correct (and counts towards precision) if the direction of
the effect estimated matches the reference set and the effect size is larger than
a specific effect size threshold. Recall is the fraction of correctly recovered
positive controls. Precision and recall at different effect size thresholds are
plotted as a precision-recall plot that summarizes the performance of each
of the three inference methods over a range of possible thresholds.
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Figure 3: Precision and Recall of effect estimates computed on Optum claims
data for 288 controls in the OMOP reference set and 68 controls in the EU-
ADR reference set. An estimate for a positive control is considered correct
(and counts towards precision) if the direction of the effect estimated matches
the reference set and the effect size is larger than a specific effect size thresh-
old. Recall is the fraction of correctly recovered positive controls. Precision
and recall at different effect size thresholds are plotted as a precision-recall
plot that summarizes the performance of each of the three inference methods
over a range of possible thresholds.
12
References
[1] K. Al-Baimani, H. Jonker, T. Zhang, G. D. Goss, S. A. Laurie,
G. Nicholas, and P. Wheatley-Price. Are clinical trial eligibility criteria
an accurate reflection of a real-world population of advanced non-small-
cell lung cancer patients? Curr Oncol, 25(4):e291–e297, 08 2018.
[2] Peter C. Austin. Variance estimation when using inverse probabil-
ity of treatment weighting (iptw) with survival analysis. Statistics in
Medicine, 35(30):5642–5655, 2016.
[3] Onur Baser. Choosing propensity score matching over regression adjust-
ment for causal inference: when, why and how it makes sense. Journal
of Medical Economics, 10(4):379–391, 01 2007.
[4] Yoav Benjamini and Yosef Hochberg. Controlling the false discovery
rate: A practical and powerful approach to multiple testing. Journal of
the Royal Statistical Society. Series B (Methodological), 57(1):289–300,
1995.
[5] M. L. Berger, H. Sox, R. J. Willke, D. L. Brixner, H. G. Eichler,
W. Goettsch, D. Madigan, A. Makady, S. Schneeweiss, R. Tarricone,
S. V. Wang, J. Watkins, and C. Daniel Mullins. Good practices for
real-world data studies of treatment and/or comparative effectiveness:
Recommendations from the joint ISPOR-ISPE Special Task Force on
real-world evidence in health care decision making. Pharmacoepidemiol
Drug Saf, 26(9):1033–1039, Sep 2017.
[6] Olivier Bodenreider. The unified medical language system (umls): in-
tegrating biomedical terminology. Nucleic acids research, 32(Database
issue):D267–D270, 01 2004.
[7] Christopher M. Callahan. Glass houses and the glory of the climb.
Annals of Internal Medicine, 135(8_Part_1):613–615, 2001. PMID:
11601934.
[8] M. Soledad Cepeda, Ray Boston, John T. Farrar, and Brian L. Strom.
Comparison of Logistic Regression versus Propensity Score When the
Number of Events Is Low and There Are Multiple Confounders. Amer-
ican Journal of Epidemiology, 158(3):280–287, 08 2003.
[9] S. Y. Chew, M. S. Koh, C. M. Loo, J. Thumboo, S. Shantakumar, and
D. B. Matchar. Making Clinical Practice Guidelines Pragmatic: How
13
Big Data and Real World Evidence Can Close the Gap. Ann. Acad.
Med. Singap., 47(12):523–527, Dec 2018.
[10] Rory Collins, Louise Bowman, Martin Landray, and Richard Peto. The
magic of randomization versus the myth of real-world evidence. New
England Journal of Medicine, 382(7):674–678, 2020/05/26 2020.
[11] P. M. Coloma, P. Avillach, F. Salvo, M. J. Schuemie, C. Ferrajolo,
A. Pariente, A. Fourrier-R?glat, M. Molokhia, V. Patadia, J. van der
Lei, M. Sturkenboom, and G. Trifir? A reference standard for evaluation
of methods for drug safety signal detection using electronic healthcare
record databases. Drug Saf, 36(1):13–23, Jan 2013.
[12] Office of the Commissioner. Real-world evidence, 2020.
[13] Richard K Crump, V. Joseph Hotz, Guido W Imbens, and Oscar A Mit-
nik. Moving the goalposts: Addressing limited overlap in the estimation
of average treatment effects by changing the estimand. Working Paper
330, National Bureau of Economic Research, October 2006.
[14] Issa J. Dahabreh and David M. Kent. Can the Learning Health Care
System Be Educated With Observational Data? JAMA, 312(2):129–
130, 07 2014.
[15] N. J. DeVito, S. Bacon, and B. Goldacre. Compliance with legal re-
quirement to report clinical trial results on ClinicalTrials.gov: a cohort
study. Lancet, 395(10221):361–369, 02 2020.
[16] Michael P. Fay. Confidence intervals that match fisher’s exact or blaker’s
exact tests. Biostatistics, 11(2):373–374, 2010.
[17] Saurabh Gombar, Alison Callahan, Robert Califf, Robert Harrington,
and Nigam H. Shah. It is time to learn from patients like mine. npj
Digital Medicine, 2(1):16, 2019.
[18] Saurabh Gombar, Alison Callahan, Robert Califf, Robert Harrington,
and Nigam H. Shah. It is time to learn from patients like mine. npj
Digital Medicine, 2(1):16, 2019.
[19] Bill Dreitlein Chris Henshall Steven D. Pearson Grace Hampson,
Adrian Towse. Real world evidence for coverage decisions: Opportu-
nities and challenges. Technical report, Institute For Clinical And Eco-
nomic Review, March 2018.
14
[20] Sean Hennessy and Charles E. Leonard. Comment on: “desideratum for
evidence-based epidemiology”. Drug Safety, 38(1):101–103, 2015.
[21] Michael D. Hughes and Paige L. Williams. Challenges in using obser-
vational studies to evaluate adverse effects of treatment. New England
Journal of Medicine, 356(17):1705–1707, 2020/05/26 2007.
[22] A. Krauss. Why all randomised controlled trials produce biased results.
Ann. Med., 50(4):312–322, 06 2018.
[23] S Liu, Wei Ma, R Moore, V. Ganesan, and S Nelson. Rxnorm: Prescrip-
tion for electronic drug information exchange. IT Professional, 7:17– 23,
10 2005.
[24] R. A. Miksad and A. P. Abernethy. Harnessing the Power of Real-
World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data
Quality. Clin. Pharmacol. Ther., 103(2):202–205, 02 2018.
[25] James M. Robins. Marginal structural models versus structural nested
models as tools for causal inference. In M. Elizabeth Halloran and Don-
ald Berry, editors, Statistical Models in Epidemiology, the Environment,
and Clinical Trials, pages 95–133, New York, NY, 2000. Springer New
York.
[26] Paul R. Rosenbaum and Donalb B. Rubin. The central role of the
propensity score in observational studies for causal effects. Biometrika,
70(1):41–55, 04 1983.
[27] P. B. Ryan, M. J. Schuemie, E. Welebob, J. Duke, S. Valentine, and
A. G. Hartzema. Defining a reference set to support methodological
research in drug safety. Drug Saf, 36 Suppl 1:33–47, Oct 2013.
[28] Martijn J. Schuemie, M. Soledad Cepeda, Marc A. Suchard, Jianxiao
Yang, Yuxi Tian , Alejandro Schuler, Patrick B. Ryan, David Madigan,
and George Hripcsak . How confident are we about observational find-
ings in health care: A benchmark study. Harvard Data Science Review,
2(1), 1 2020. https://hdsr.mitpress.mit.edu/pub/fxz7kr65.
[29] Martijn J. Schuemie, Rosa Gini, Preciosa M. Coloma, Huub Straat-
man, Ron M. C. Herings, Lars Pedersen, Francesco Innocenti, Gi-
ampiero Mazzaglia, Gino Picelli, Johan van der Lei, and Miriam C.
J. M. Sturkenboom. Replication of the omop experiment in europe:
Evaluating methods for risk identification in electronic health record
databases. Drug Safety, 36(1):159–169, 2013.
15
[30] Alejandro Schuler, Alison Callahan, Kenneth Jung, and Nigam H. Shah.
Performing an informatics consult: Methods and challenges. Journal of
the American College of Radiology, 15(3):563–568, 2020/05/26 2018.
[31] Kenneth F. Schulz, Douglas G. Altman, David Moher, and the CON-
SORT Group. Consort 2010 statement: updated guidelines for reporting
parallel group randomised trials. BMC Medicine, 8(1):18, 2010.
[32] Ethan Steinberg, Ken Jung, Jason A. Fries, Conor K. Corbin,
Stephen R. Pfohl, and Nigam H. Shah. Language models are an ef-
fective patient representation learning technique for electronic health
record data, 2020.
[33] Marc A Suchard, Martijn J Schuemie, Harlan M Krumholz, Seng Chan
You, RuiJun Chen, Nicole Pratt, Christian G Reich, Jon Duke, David
Madigan, George Hripcsak, and Patrick B Ryan. Comprehensive
comparative effectiveness and safety of first-line antihypertensive drug
classes: a systematic, multinational, large-scale analysis. The Lancet,
394(10211):1816–1826, 2020/05/26 2019.
[34] Esteban Walker and Amy S Nowacki. Understanding equivalence and
noninferiority testing. Journal of general internal medicine, 26(2):192–
196, 02 2011.
16
